Engineered immune cells take on tough lymphoma in new trial
NCT ID NCT07288879
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new CAR T cell therapy called MB-CART2019.1 in 31 people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, genetically modified to target and kill cancer cells. The main goal is to see how many patients' tumors shrink or disappear one month after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR T cell therapy (MB-CART2019.1)
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat DLBCL that has not responded to standard therapies.
What could go wrong
This is a small, early-phase study (31 participants) with no control group. CAR T therapy can cause serious side effects like cytokine release syndrome. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Juntendo University Hospital
NOT_YET_RECRUITINGTokyo, 113-8431, Japan
-
Keio University Hospital
NOT_YET_RECRUITINGTokyo, 160-8582, Japan
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
Tokyo Metropolitan Komagome Hospital
RECRUITINGTokyo, 113-8677, Japan
-
Toranomon Hospital
NOT_YET_RECRUITINGTokyo, 105-8470, Japan